dostarlimab,pembrolizumab
Merck,GSK
[]
 i wonder about the relevance of a 2.1 months absolute difference in pfs a secondary endpoint in a phase 2 trial.
Since 1965. Observer. Medical Oncologist. Spanish Group for Breast Cancer Research (GEICAM). Álvaro Rodríguez-Lescure MD, PhD.